© 2022 MJH Life Sciences and Dermatology Times and Multimedia Medical, LLC. All rights reserved.
© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
March 23, 2022
Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.
Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.
March 16, 2022
Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.
A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.
March 09, 2022
A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.
Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.
March 02, 2022
Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.
Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.
February 07, 2022
Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.
Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.